RxDoctor Payments Data

Kaylee Schobelock

Family · Chillicothe, OHNPI 1386189207

Payments from drug & device makers

$1,658in general payments, 2019–2025

Across 72 payments — averaging $23.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$875
  • AstraZeneca$182
  • Amgen$132
  • Boston Scientific$83
  • Novartis$66
  • Johnson & Johnson$48
  • plus $273 from 10 others

What the payments were for

  • Food & beverage$1,55994%
  • Education$996%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,658 in reported general payments places this provider in the 80th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$19,084
Medicare patients
185
Services billed
277

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban118$115,794
EntrestoSacubitril/Valsartan37$53,695
Repatha SureclickEvolocumab32$30,843
BrilintaTicagrelor26$23,891
FarxigaDapagliflozin Propanediol13$18,798
XareltoRivaroxaban16$15,553
JardianceEmpagliflozin23$14,225
Metoprolol Succinate169$3,176
Ranolazine ErRanolazine36$2,741
Prasugrel Hcl24$2,718
Atorvastatin Calcium147$1,470
Diltiazem 24hr Er (Cd)Diltiazem Hcl38$1,338
Isosorbide Mononitrate ErIsosorbide Mononitrate104$1,113
Rosuvastatin Calcium52$1,045
ClopidogrelClopidogrel Bisulfate92$1,002

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$17$115,794118 claims
NovartisEntresto$66$53,69537 claims
AstraZenecaBrilinta, Farxiga$182$42,68939 claims
Johnson & JohnsonXarelto$48$15,55316 claims
Boehringer IngelheimJardiance$28$14,22523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,812 family providers in Ohio.

Other family in Chillicothe

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →